[1. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006; 4: 3-13.10.1016/j.ejcsup.2006.08.002]Search in Google Scholar
[2. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-240.10.1016/j.ejso.2007.05.01617614247]Search in Google Scholar
[3. Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G. Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005; 16: 345-348.10.1097/00001813-200503000-0001515711188]Search in Google Scholar
[4. Snoj M, Cemazar M, Srnovrsnik T, Paulin-Kosir SM, Sersa G. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori 2009; 95: 398-402.10.1177/030089160909500324]Search in Google Scholar
[5. Colombo GL, Di Matteo S, Mir LM. Cost-effectiveness analysis of electrochemotherapy with the CliniporatorTM vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag 2008; 4: 541-548.10.2147/TCRM.S2780250405218728828]Search in Google Scholar
[6. Moller MG, Salwa S, Soden DM, O’Sullivan GC. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 2009; 9: 1611-1630.10.1586/era.09.12919895245]Search in Google Scholar
[7. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, et al. Local and intralesional therapy of in-transit melanoma metastases. JSurg Oncol 2011; 104: 391-396.10.1002/jso.2202921858834]Search in Google Scholar
[8. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or noninvasive electrodes. Eur J Cancer Suppl 2006; 4: 14-25.10.1016/j.ejcsup.2006.08.003]Search in Google Scholar
[9. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 2009; 16: 191-199.10.1245/s10434-008-0204-818987914]Search in Google Scholar
[10. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardo T, Mortera C, et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2012; 19: 192-198.10.1245/s10434-011-1860-721822561]Search in Google Scholar
[11. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-2222.10.1245/s10434-008-9976-018498012]Search in Google Scholar
[12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.10.1136/bmj.b2700271467219622552]Search in Google Scholar
[13. Wieseler B, McGauran N. Reporting a systematic review. Chest 2010; 137: 1240-1246.10.1378/chest.09-262520442127]Search in Google Scholar
[14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. UK: Wiley-Blackwell; 2008.10.1002/9780470712184]Search in Google Scholar
[15. World Health Organization. WHO handbook for reporting results of cancertreatment. Switzerland: World Health Organization; 1979.]Search in Google Scholar
[16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.10.1093/jnci/92.3.20510655437]Search in Google Scholar
[17. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to metaanalysis. UK: Wiley; 2009.10.1002/9780470743386]Search in Google Scholar
[18. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Hughes TM, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15: 45-51.10.1097/00008390-200502000-0000815714120]Search in Google Scholar
[19. Landstrom FJ, Nilsson COS, Crafoord S, Reizenstein JA, Adamsson GBM, Lofgren LA. Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg 2010; 36: 1245-1250.10.1111/j.1524-4725.2010.01617.x20666812]Search in Google Scholar
[20. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O’Reily S, et al. Electrochemotherapy - Aspects of preclinical development and early clinical experience. Ann Surg 2007; 245: 469-479.10.1097/01.sla.0000250419.36053.33187702717435555]Search in Google Scholar
[21. Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 50: 621-629.10.3109/0284186X.2011.573626313099721574833]Search in Google Scholar
[22. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000; 10: 468-474.10.1097/00008390-200010000-00009]Search in Google Scholar
[23. Domenge C, Orlowski S, Luboinski B, DeBaere T, Schwaab G, Belehradek J, et al. Antitumor electrochemotherapy - New advances in the clinical protocol. Cancer 1996; 77: 956-963.10.1002/(SICI)1097-0142(19960301)77:5<956::AID-CNCR23>3.0.CO;2-1]Search in Google Scholar
[24. Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998; 74: 2152-2158.10.1016/S0006-3495(98)77924-X]Search in Google Scholar
[25. Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. EurJ Cancer Suppl 2006; 4: 45-51.10.1016/j.ejcsup.2006.08.006]Search in Google Scholar
[26. Miklavcic D, Towhidi L. Numerical study of the electroporation pulse shape effect on molecular uptake of biological cells. Radiol Oncol 2010; 44: 34-41.10.2478/v10019-010-0002-3]Search in Google Scholar
[27. Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs 1998; 9: 525-530.10.1097/00001813-199807000-00002]Search in Google Scholar
[28. Front D, Israel O, Iosilevsky G, Even-Sapir E, Ben-Haim S, Frenkel A, et al. Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. J Nucl Med 1990; 31: 1784-1790.]Search in Google Scholar
[29. Mir LM, Tounekti O, Orlowski S. Bleomycin: Revival of an old drug. GenPharmac 1996; 27: 745-748.10.1016/0306-3623(95)02101-9]Search in Google Scholar
[30. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982; 9: 22-25.10.1007/BF00296756]Search in Google Scholar
[31. Alberts DS, Chen HS, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, et al. Bleomycin pharmacokinetics in man. I. Intravenous administration. CancerChemother Pharmacol 1978; 1: 177-181.]Search in Google Scholar
[32. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-398.10.1038/sj.bjc.6604168]Search in Google Scholar
[33. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002; 87: 1047-1054.10.1038/sj.bjc.6600606]Search in Google Scholar
[34. Sersa G, Cemazar M, Miklavcic D. Tumor blood flow modifying effects of electrochemotherapy: a potential vascular targeted mechanism. RadiolOncol 2003; 37: 43-48.]Search in Google Scholar
[35. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. ExpertRev Anticancer Ther 2010; 10: 729-746.10.1586/era.10.4320470005]Search in Google Scholar
[36. Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. BioMed Eng OnLine 2010; 9: 10.10.1186/1475-925X-9-10284368420178589]Search in Google Scholar
[37. Edhemovic I, Gadzijev EM, Brecelj E, MIklavcic M, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475-485.10.7785/tcrt.2012.500224452741421895032]Search in Google Scholar
[38. Pavliha D, Kos B, Zupanic A, Marcan M, Sersa G, Miklavcic D. Patient-specific treatment planning of electrochemotherapy: Procedure design and possible pitfalls. Bioelectrochemistry 2012; 87: 265-273.10.1016/j.bioelechem.2012.01.00722341626]Search in Google Scholar
[39. Adeyanju OO, Al-Angari HM, Sahakian AV. The optimization of needle electrode number and placement for irreversible electroporation of hepatocellular carcinoma. Radiol Oncol 2012; 46: 126-135.10.2478/v10019-012-0026-y347294023077449]Search in Google Scholar